These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Pathomechanisms in celiac disease. Dieterich W; Esslinger B; Schuppan D Int Arch Allergy Immunol; 2003 Oct; 132(2):98-108. PubMed ID: 14600421 [TBL] [Abstract][Full Text] [Related]
5. Celiac disease: risk assessment, diagnosis, and monitoring. Setty M; Hormaza L; Guandalini S Mol Diagn Ther; 2008; 12(5):289-98. PubMed ID: 18803427 [TBL] [Abstract][Full Text] [Related]
6. Celiac disease: epidemiology, pathogenesis, diagnosis, and nutritional management. Schuppan D; Dennis MD; Kelly CP Nutr Clin Care; 2005; 8(2):54-69. PubMed ID: 16013224 [TBL] [Abstract][Full Text] [Related]
7. Celiac disease: from pathogenesis to novel therapies. Schuppan D; Junker Y; Barisani D Gastroenterology; 2009 Dec; 137(6):1912-33. PubMed ID: 19766641 [TBL] [Abstract][Full Text] [Related]
8. Celiac disease: how complicated can it get? Tjon JM; van Bergen J; Koning F Immunogenetics; 2010 Oct; 62(10):641-51. PubMed ID: 20661732 [TBL] [Abstract][Full Text] [Related]
9. Celiac disease--sandwiched between innate and adaptive immunity. Stepniak D; Koning F Hum Immunol; 2006 Jun; 67(6):460-8. PubMed ID: 16728270 [TBL] [Abstract][Full Text] [Related]
10. Celiac disease: caught between a rock and a hard place. Koning F Gastroenterology; 2005 Oct; 129(4):1294-301. PubMed ID: 16230082 [TBL] [Abstract][Full Text] [Related]
11. T-cell and B-cell immunity in celiac disease. du Pré MF; Sollid LM Best Pract Res Clin Gastroenterol; 2015 Jun; 29(3):413-23. PubMed ID: 26060106 [TBL] [Abstract][Full Text] [Related]
12. Plasma Cells Are the Most Abundant Gluten Peptide MHC-expressing Cells in Inflamed Intestinal Tissues From Patients With Celiac Disease. Høydahl LS; Richter L; Frick R; Snir O; Gunnarsen KS; Landsverk OJB; Iversen R; Jeliazkov JR; Gray JJ; Bergseng E; Foss S; Qiao SW; Lundin KEA; Jahnsen J; Jahnsen FL; Sandlie I; Sollid LM; Løset GÅ Gastroenterology; 2019 Apr; 156(5):1428-1439.e10. PubMed ID: 30593798 [TBL] [Abstract][Full Text] [Related]
13. Transglutaminase 2-targeted autoantibodies in celiac disease: Pathogenetic players in addition to diagnostic tools? Lindfors K; Mäki M; Kaukinen K Autoimmun Rev; 2010 Sep; 9(11):744-9. PubMed ID: 20547248 [TBL] [Abstract][Full Text] [Related]
14. The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase. Arentz-Hansen H; Körner R; Molberg O; Quarsten H; Vader W; Kooy YM; Lundin KE; Koning F; Roepstorff P; Sollid LM; McAdam SN J Exp Med; 2000 Feb; 191(4):603-12. PubMed ID: 10684852 [TBL] [Abstract][Full Text] [Related]
15. Small-bowel mucosal transglutaminase 2-specific IgA deposits in coeliac disease without villous atrophy: a prospective and randomized clinical study. Kaukinen K; Peräaho M; Collin P; Partanen J; Woolley N; Kaartinen T; Nuutinen T; Halttunen T; Mäki M; Korponay-Szabo I Scand J Gastroenterol; 2005 May; 40(5):564-72. PubMed ID: 16036509 [TBL] [Abstract][Full Text] [Related]
19. The molecular basis of celiac disease. Koning F J Mol Recognit; 2003; 16(5):333-6. PubMed ID: 14523946 [TBL] [Abstract][Full Text] [Related]
20. A role for anti-transglutaminase 2 autoantibodies in the pathogenesis of coeliac disease? Lindfors K; Kaukinen K; Mäki M Amino Acids; 2009 Apr; 36(4):685-91. PubMed ID: 18594945 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]